Multi-institutional retrospective study for advanced lung cancer patients with end-stage kidney disease on hemodialysis (NEJ-042) - NEJ-042 study

Specified Nonprofit Corporation North East Japan Study Group0 个研究点目标入组 162 人开始时间: 2019年4月1日最近更新: 2023年10月17日

研究概览

简要总结

Chemotherapy should be considered for hemodialysis patients with EGFR-mutant NSCLC and SCLC. However, the survival benefits of chemotherapy for NSCLC patients with EGFR-wild type are unclear; physicians should carefully consider whether to offer chemotherapy to this patient subset.

研究设计

研究类型: Observational

入排标准

年龄范围: ot applicable 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•Patient, or family refuses to participate in the study

研究者

发起方

Specified Nonprofit Corporation North East Japan Study Group

相似试验

招募中

2 期

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLCNon-Small Cell Lung Cancer

NCT06718309First People's Hospital of Hangzhou40

已完成

2 期

Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / DocetaxelNon Small Cell Lung Cancer

NCT01222312Krankenhaus Nordwest88

进行中（未招募）

1 期

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Non-Small Cell Lung Cancer

NCT03974022Dizal Pharmaceuticals315

进行中（未招募）

1 期

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Non Small Cell Lung Cancer

NCT04743505Washington University School of Medicine27

已完成

2 期

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationNon Small Cell Lung Cancer MetastaticLeptomeningeal MetastasisBrain MetastasesEGFR Activating Mutation

NCT04233021Intergroupe Francophone de Cancerologie Thoracique57